Publicaciones científicas

Altered Concentrations in Dyslipidemia Evidence a Role for ANGPTL8/Betatrophin in Lipid Metabolism in Humans

Gómez-Ambrosi J (1), Pascual-Corrales E (1), Catalán V (1), Rodríguez A (1), Ramírez B (1), Romero S (1), Vila N (1), Ibáñez P (1), Margall MA (1), Silva C (1), Gil MJ (1), Salvador J (1), Frühbeck G (1).
(1) Metabolic Research Laboratory (J.G.-A., V.C., A.R., B.R., G.F.) and Departments of Endocrinology and Nutrition (E.P.-C., S.R., N.V., P.I., M.A.M., C.S., J.S., G.F.) and Biochemistry (M.J.G.), Clínica Universidad de Navarra, 31008 Pamplona, Spain; CIBER Fisiopatología de la Obesidad y Nutrición (CIBEROBN) (J.G.-A., V.C., A.R., B.R., S.R., P.I., C.S., M.J.G., J.S., G.F.), Instituto de Salud Carlos III, 31008 Pamplona, Spain; and Obesity and Adipobiology Group, Instituto de Investigación Sanitaria de Navarra (IdiSNA) (J.G.-A., V.C., A.R., B.R., S.R., N.V., P.I., M.A.M., C.S., M.J.G., G.F.), 31008 Pamplona, Spain 

Revista: The Journal of Clinical Endocrinology and Metabolism

Fecha: 29-jul-2016

Endocrinología y Nutrición Bioquímica Clínica Área de Obesidad

CONTEXT:
ANGPTL8/betatrophin is a secreted protein initially involved in β-cell replication. Recent data in humans and mice models suggest that ANGPTL8/betatrophin is more related to lipid metabolism.

OBJECTIVE:
The aim of the present study was to compare the circulating concentrations of ANGPTL8/betatrophin in individuals with dyslipidemia defined as having high or low levels of HDL-cholesterol or triglycerides, respectively.

DESIGN, SETTING, AND PARTICIPANTS:
Serum concentrations of ANGPTL8/betatrophin were measured by ELISA in 177 subjects. We studied two different selected case-control dyslipidemic cohorts including individuals with high (n=43) or low (n=46) circulating concentrations of HDL-cholesterol or with low (n=48) or high (n=40) levels of triglycerides.

RESULTS:
Circulating concentrations of ANGPTL8/betatrophin were significantly lower in individuals with dyslipidemia P<0.001 in both males (C 27.8 ± 15.2 vs DL 17.0 ± 11.2 ng/mL) and females (C 50.0 ± 22.2 vs DL 27.0 ± 16.5 ng/mL). The magnitude of the differences was higher in dyslipidemic patients with low HDL-cholesterol than in those with high TG concentrations. ANGPTL8/betatrophin levels were lower in subjects with T2D (P<0.001) but the impact of T2D vanished (P=0.257) when the effect of dyslipidemia was included in the analysis.

CONCLUSIONS:
We conclude that serum ANGPTL8/betatrophin concentrations are altered in human dyslipidemia. ANGPTL8/betatrophin emerges as a potential player in dyslipidemia with a strong association with HDL-C and a potential therapeutic tool for the treatment of dyslipidemia.

CITA DEL ARTÍCULO  J Clin Endocrinol Metab. 2016 Jul 29:jc20162084

tal vezLE INTERESE

¿QUÉ TECNOLOGÍA UTILIZAMOS?

La Clínica es el hospital privado con mayor dotación tecnológica de España, todo en un único centro.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

NUESTROS
PROFESIONALES

Los profesionales de la Clínica realizan una labor continuada de investigación y formación, siempre en beneficio del paciente.

Imagen profesionales de la Clínica Universidad de Navarra

POR QUÉ VENIR
A LA CLÍNICA

Conozca por qué somos diferentes a otros centros sanitarios. Calidad, rapidez, comodidad y resultados.

Imagen del edificio de la Clínica Universidad de Navarra